Felzartamab (MOR-202) 是一种人源的靶向CD38的单克隆抗体，可用于多发性骨髓瘤研究。
| 生物活性 | Felzartamab (MOR-202) is a human monoclonal antibody that targetsCD38and can be used in multiple myeloma research[1][2]. |
体外研究
(In Vitro) | The MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN)[1].
|
体内研究
(In Vivo) | MOR202 can reduce osteolysis dose-dependently by up to 55% at 12 mg/kg. Co-administration with 0.6 mg/kg BOR or 50 mg/kg LEN at a low dose of 3 mg/kg completely eliminates osteolysis in mice MM model[1].
|
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
